Alejandro Falcon
Sevilla, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.
Journal: ESMO open
Published: November 25, 2025
UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: November 24, 2025
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 09, 2025
Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 25, 2025
Multidisciplinary management of persistent severe cancer pain: a collaborative European approach.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: January 24, 2025
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 29, 2024
Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.
Journal: Therapeutic advances in medical oncology
Published: August 12, 2024
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Journal: Nature medicine
Published: October 18, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Journal: The New England journal of medicine
Published: August 23, 2023
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer.
Journal: International journal of molecular sciences
Published: April 04, 2023
Last Updated: 09/26/2026